RT Journal Article
SR Electronic
T1 Microplastics Identified in Commercial Over-the-counter Lubricant Eyedrops
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.26.24307941
DO 10.1101/2024.05.26.24307941
A1 Jaeger, Julia E
A1 Burke, Matthew
A1 Wu, Duoduo
A1 Curren, Emily Ern-Min
A1 Yew Leong, Sandric Chee
A1 Symons, Robert
A1 Lim, Blanche Xiao Hong
A1 Su, Xinyi
A1 Mehta, Jodhbir Singh
A1 Riau, Andri Kartasasmita
A1 Lim, Chris Hong Long
YR 2024
UL http://medrxiv.org/content/early/2024/05/28/2024.05.26.24307941.abstract
AB Purpose There is increasing evidence that microplastics exert harmful effects on human health and on the ocular surface. Recent studies have highlighted the presence of ocular surface exposure to microplastics via shedding from contact lenses. This study aims to investigate if microplastic particles are present in commonly used eyedrops in single-use plastic vials.Design Experimental study.Methods Nine commonly used commercial tear-replacement solutions available without a doctor’s prescription were tested (Brands A-I). All brands of eyedrops were analysed visually using light microscopy and the number of microplastic particles were manually counted. Brands A-F were further analysed using the 8700 Agilent Laser Direct Infrared (LDIR) chemical imaging system to identify the microplastic compositions.Results All eyedrops analysed contained microplastics. The number of microplastic particles identified using light microscopy ranged between 15 (Brand E) to >18,000 (Brand F). In total, nine types of microplastics were identified with LDIR – an average of 14 polyethylene, 8 polypropylene, 1 polystyrene, 2 polyvinylchloride, 21 polyethylene terephthalate, 1 polycarbonate, 19 polymethylmethacrylate, 23 polyamide and 22 polyurethane per millilitre of eyedrop were identified.Conclusions This is the first study that identified microplastics in commercial tear-replacement solutions. These particles may have been derived from secondary degradation of the plastic vials (polyethylene) during production, transportation, or storage, and represent a major source of exposure to the ocular surface, especially among patients who require chronic instillation of eyedrops.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was partly funded by the SERI-Lee Foundation Grant (R1845/87/2021).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript